Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153(5):804–e8141. https://doi.org/10.1016/j.ajo.2011.10.024.

Article  PubMed  PubMed Central  Google Scholar 

Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology. 1991;98(7):1053–60.

Article  CAS  PubMed  Google Scholar 

Saheb H, Gedde SJ, Schiffman JC, Feuer WJ. Outcomes of glaucoma reoperations in the Tube Versus Trabeculectomy (TVT) study. Am J Ophthalmol. 2014;157(6):1179–e11892. https://doi.org/10.1016/j.ajo.2014.02.027.

Article  PubMed  PubMed Central  Google Scholar 

Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl1):S57–68. https://doi.org/10.1016/j.survophthal.2008.08.002.

Article  PubMed  Google Scholar 

Hennessy AL, Katz J, Covert D, Protzko C, Robin AL. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. Ophthalmology. 2010;117(12):2345–52. https://doi.org/10.1016/j.ophtha.2010.03.040.

Article  PubMed  Google Scholar 

Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–5. https://doi.org/10.1097/IJG.0b013e31815c5f4f.

Article  PubMed  Google Scholar 

Schehlein EM, Im LT, Robin AL, Onukwugha E, Saeedi OJ. Nonmedical out-of-Pocket patient and Companion expenditures Associated with Glaucoma care. J Glaucoma 9000;Publish Ah. http://journals.lww.com/glaucomajournal/Fulltext/publishahead/Nonmedical_Out_of_Pocket_Patient_and_Companion.98781.aspx.

Arora KS, Robin AL, Corcoran KJ, Corcoran SL, Ramulu PY. Use of various Glaucoma surgeries and procedures in Medicare Beneficiaries from 1994 to 2012. Ophthalmology. 2015;122(8):1615–24. https://doi.org/10.1016/j.ophtha.2015.04.015.

Article  PubMed  Google Scholar 

Rathi S, Andrews CA, Greenfield DS, Stein JD. Trends in Glaucoma surgeries performed by Glaucoma subspecialists versus nonsubspecialists on Medicare Beneficiaries from 2008 through 2016. Ophthalmology. 2021;128(1):30–8. https://doi.org/10.1016/j.ophtha.2020.06.051.

Article  PubMed  Google Scholar 

Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ. 2004;82(11):887–8. doi:/S0042-96862004001100019.

PubMed  PubMed Central  Google Scholar 

Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505–16. Pivotal study that compared SLT with topical drops as first-line treatment. This study found that SLT is an appropriate first line treatment for glaucoma resulting in lower intraocular pressure lowering and delay in visual field loss.

Article  PubMed  PubMed Central  Google Scholar 

Goldenfeld M, Belkin M, Dobkin-Bekman M, et al. Automated direct selective laser trabeculoplasty: first prospective clinical trial. Transl Vis Sci Technol. 2021;10(3):5.

Article  PubMed  PubMed Central  Google Scholar 

Figus M, Posarelli C, Passani A, et al. The supraciliary space as a suitable pathway for glaucoma surgery: ho-hum or home run? Surv Ophthalmol. 2017;62(6):828–37. https://doi.org/10.1016/j.survophthal.2017.05.002.

Article  PubMed  Google Scholar 

Denis P, Hirneiß C, Reddy KP, et al. A first-in-human study of the efficacy and safety of MINIject in patients with medically uncontrolled open-angle glaucoma (STAR-I). Ophthalmol Glaucoma. 2019;2(5):290–7.

Article  PubMed  Google Scholar 

Ianchulev T, Weinreb RN, Kamthan G et al. Biotissue stent for supraciliary outflow in open-angle glaucoma patients: surgical procedure and first clinical results of an aqueous drainage biostent British Journal of Ophthalmology published Online First: 02 January 2023. https://doi.org/10.1136/bjo-2022-322536.

Voskanyan L, Papoyan V, Sourdille P, Benoit O, Miroyan H. Supraciliary drainage without entering the anterior chamber and without bleb: 24 months follow up results. Rome, Italy: Poster presented at World Glaucoma Congress; June 2023.

**Sheybani A, Vera V, Grover DS, Vold SD, Cotter F, Bedrood S, Sawhney G, Piette SD, Simonyi S, Gu X, Balaram M, Gallardo MJ. Gel Stent Versus Trabeculectomy: The Randomized, Multicenter, Gold-Standard Pathway Study (GPS) of Effectiveness and Safety at 12 Months. Am J Ophthalmol. 2023; 252:306–325. https://doi.org/10.1016/j.ajo.2023.03.026. Epub 2023 Mar 25. PMID: 36972738. Multicenter, randomized prospective study comparing Xen gel stent to trabeculectomy which showed the gel stent was noninferior to trabeculectomy and had few surgical complications and subjective improvement of QOL for the patient.

Evers C, Böhringer D, Kallee S, Keye P, Philippin H, Piotrowski T, Reinhard T, Lübke J. XEN®-63 compared to XEN®-45 gel stents to reduce intraocular pressure in Glaucoma. J Clin Med. 2023;12(15):5043. https://doi.org/10.3390/jcm12155043. PMID: 37568443; PMCID: PMC10419806.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beckers HJM, Aptel F, Webers CAB, Bluwol E, Martínez-de-la-Casa JM, García-Feijoó J, Lachkar Y, Méndez-Hernández CD, Riss I, Shao H, Pinchuk L, Angeles R, Sadruddin O, Shaarawy TM. Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma: results from a 2-Year Multicenter Study. Ophthalmol Glaucoma. 2022 Mar-Apr;5(2):195–209. doi: 10.1016/j.ogla.2021.07.008. Epub 2021 Jul 28. PMID: 34329772.

Charters L. PAUL implant: Good IOP lowering, fewer complications compared with Baerveldt device. europeophthalmologytimescom. 2023;19:11–12. Accessed October 3, 2023. https://europe.ophthalmologytimes.com/view/paul-implant-good-iop-lowering-fewer-complications-compared-with-baerveldt-device.

PAUL Glaucoma Implant Brochure. Advanced Ophthalmic Innovations. Accessed October 5. 2023. https://aoi.sg/wp-content/uploads/2022/08/PAUL-Brochure-Print_2022.pdf.

Clinical Benefits. Rheon Medical. Accessed October 5. 2023. https://rheonmedical.com/physicians/clinical-benefits/.

Blum K. OIS Glaucoma Showcase Take-Home: Glaucoma Market Poised For Growth. Ophthalmology Innovation Source. Published October 26, 2021. Accessed October 6, 2023. https://ois.net/ois-glaucoma-showcase-take-home-glaucoma-market-poised-for-growth-disruption/.

MIMS Clinical Data. www.sanoculis.com. Accessed October 6. 2023. https://www.sanoculis.com/clinical.

Bicket AK, Szeto J, Roeber P, Towler J, Troutman M, Craven ER, Khatana A, Ahmed I, Quigley H, Ramulu P, Pitha IF. A novel bilayered expanded polytetrafluoroethylene glaucoma implant creates a permeable thin capsule independent of aqueous humor exposure. Bioeng Transl Med. 2020;6(1):e10179. https://doi.org/10.1002/btm2.10179. PMID: 33532583; PMCID: PMC7823119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hennessy AL, Katz J, Covert D, et al. A video study of drop instillation in both glaucoma and retina patients with visual impairment. Am J Ophthalmol. 2011;152(6):982–8. https://doi.org/10.1016/j.ajo.2011.05.015.

Article  PubMed  Google Scholar 

Blumberg DM, Prager AJ, Liebmann JM, Cioffi GA, De Moraes CG. Cost-related medication nonadherence and cost-saving behaviors among patients with Glaucoma before and after the implementation of Medicare Part D. JAMA Ophthalmol. 2015;133(9):985–96. https://doi.org/10.1001/jamaophthalmol.2015.1671.

Article  PubMed  Google Scholar 

Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36(5):391–8. https://doi.org/10.3109/02713683.2011.562340.

Article  PubMed  Google Scholar 

Mansberger SL, Conley J, Verhoeven RS, et al. Interim analysis of low dose ENV515 travoprost XR with 11 Month Duration followed by dose escalation and 28 day efficacy evaluation of high dose ENV515. Invest Ophthalmol Vis Sci. 2017;58(8):2110.

Google Scholar 

Goldstein MH, Goldberg D, Walters TR, Vantipalli S, Braun E, Metzinger JL. Evaluating Safety, Tolerability and Efficacy of an Intracameral Hydrogel-based Travoprost Implant in subjects with Glaucoma - phase 1 trial. Invest Ophthalmol Vis Sci. 2020;61(7):4266.

Google Scholar 

Butchofsky B, Mati. Punctal Plugs for Sustained Delivery. Ophthalmology Innovation Source. https://ois.net/punctal-plugs-for-sustained-delivery/. Published 2023. Accessed October 14, 2023.

Inc MT. Safety and intraocular lowering effect of delivery of Travoprost Evolute® in subjects with elevated intraocular pressure.; 2023. NCT04962009.

Brandt JD, DuBiner HB, Benza R, Sall KN, Walker GA, Semba CP. Long-term safety and efficacy of a sustained-release Bimatoprost Ocular Ring. Ophthalmology. 2017;124(10):1565–6. https://doi.org/10.1016/j.ophtha.2017.04.022.

Article  PubMed  Google Scholar 

Brandt JD, Sall K, DuBiner H et al. May. Six-Month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology. 2016. https://doi.org/10.1016/j.ophtha.2016.04.026.

Katz LJ, Sarkisian SR, Voskanyan LA, et al. Results of the prospective, randomized, controlled, multicenter phase 3 trials of the travoprost intraocular implant versus topical timolol. Invest Ophthalmol Vis Sci. 2023;64(8):4296.

Google Scholar 

Hutton D. PolyActiva offers results of Phase IIa study of ocular implant. Ophthalmology Times. https://www.ophthalmologytimes.com/view/polyactiva-offers-results-of-phase-iia-study-of-ocular-implant. Published 2022. Accessed October 14, 2023.

Roy S, Villamarin A, Stergiopulos C, et al. Comparison between the eyeWatch device and the Ahmed Valve in Refractory Glaucoma. J Glaucoma. 2020;29(5):401–5. https://doi.org/10.1097/IJG.0000000000001471.

Article  PubMed  Google Scholar 

Pharma S. Published SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions. GlobeNewswire. https://www.globenewswire.com/en/news-release/2023/02/03/2601509/0/en/SpyGlass-Pharma-Unveils-6-Month-Data-from-the-First-In-Human-Trial-of-Its-Innovative-Drug-Delivery-Platform-for-Chronic-Eye-Conditions.html. 2023. Accessed October 15, 2023.